Pelthos Buys Impetigo Treatment From Biofrontera, Ferrer
Pelthos Therapeutics Inc. has acquired the US commercialization rights to ozenoxacin cream, 1% (Xepi) from Biofrontera Inc. and Ferrer Internacional S.A.
Category: Headlines in Dermatology
Pelthos Therapeutics Inc. has acquired the US commercialization rights to ozenoxacin cream, 1% (Xepi) from Biofrontera Inc. and Ferrer Internacional S.A.